10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

LILRB4 Antibody (N-term) Blocking peptide
Synthetic peptide
Catalog # BP12297a

Specification

LILRB4 Antibody (N-term) Blocking peptide - Product Information

Primary Accession Q8NHJ6

LILRB4 Antibody (N-term) Blocking peptide - Additional Information

Gene ID 11006

Other Names
Leukocyte immunoglobulin-like receptor subfamily B member 4, CD85 antigen-like family member K, Immunoglobulin-like transcript 3, ILT-3, Leukocyte immunoglobulin-like receptor 5, LIR-5, Monocyte inhibitory receptor HM18, CD85k, LILRB4, ILT3, LIR5

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

LILRB4 Antibody (N-term) Blocking peptide - Protein Information

Name LILRB4

Synonyms ILT3, LIR5

Function
Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance (PubMed:11875462). Receptor for FN1 (PubMed:34089617). Receptor for apolipoprotein APOE (PubMed:30333625). Receptor for ALCAM/CD166 (PubMed:29263213). Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:9151699). Inhibits FCGR1A/CD64-mediated monocyte activation by inducing phosphatase-mediated down-regulation of the phosphorylation of multiple proteins including LCK, SYK, LAT and ERK, leading to a reduction in TNF production (PubMed:19833736). This inhibition of monocyte activation occurs at least in part via binding to FN1 (PubMed:<a

href="http://www.uniprot.org/citations/34089617" target="_blank">34089617). Inhibits T cell proliferation, inducing anergy, suppressing the differentiation of IFNG-producing CD8+ cytoxic T cells and enhancing the generation of CD8+ T suppressor cells (PubMed:16493035, PubMed:19833736, PubMed:29263213). Induces up-regulation of CD86 on dendritic cells (PubMed:19860908). Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation (PubMed:11875462).

Cellular Location
Cell membrane; Single-pass type I membrane protein. Note=Ligand binding leads to internalization and translocation to an antigen-processing compartment

Tissue Location
Detected on monocytes, macrophages, dendritic cells, natural killer cells and B-cells (at protein level). Expressed in the lung.

LILRB4 Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

LILRB4 Antibody (N-term) Blocking peptide - Images

LILRB4 Antibody (N-term) Blocking peptide - Background

This gene is a member of the leukocyte immunoglobulin-likereceptor (LIR) family, which is found in a gene cluster atchromosomal region 19q13.4. The encoded protein belongs to thesubfamily B class of LIR receptors which contain two or fourextracellular immunoglobulin domains, a transmembrane domain, andtwo to four cytoplasmic immunoreceptor tyrosine-based inhibitorymotifs (ITIMs). The receptor is expressed on immune cells where itbinds to MHC class I molecules on antigen-presenting cells andtransduces a negative signal that inhibits stimulation of an immuneresponse. The receptor can also function in antigen capture andpresentation. It is thought to control inflammatory responses andcytotoxicity to help focus the immune response and limitautoreactivity. Multiple transcript variants encoding differentisoforms have been found for this gene.

LILRB4 Antibody (N-term) Blocking peptide - References

Davila, S., et al. Genes Immun. 11(3):232-238(2010)Lu, H.K., et al. J. Biol. Chem. 284(50):34839-34848(2009)Jones, D.C., et al. Eur. J. Immunol. 39(11):3195-3206(2009)Brenk, M., et al. J. Immunol. 183(1):145-154(2009)Brown, D.P., et al. BMC Immunol. 10, 56 (2009) :